Engineers Gate Manager LP Rubius Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $1,325 - $10,034	-1,678 Reduced 8.97%	17,022 $14,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $34,641 - $84,770	8,151 Added 77.27%	18,700 $103,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $102,114 - $187,139	10,549 New	10,549 $102,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $158,593 - $233,475	-9,011 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $200,584 - $256,182	9,011 New	9,011 $220,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $42,300 - $87,300	-10,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $46,500 - $62,500	10,000 New	10,000 $50,000
Q2 2020 Aug 17, 2020	SELL	$4.01 - $6.88 $42,907 - $73,616	-10,700 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.74 - $9.84 $40,018 - $105,288	10,700 New	10,700 $48,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.